Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 12, 2026MicroOpen Access

Nanoparticle-Based Drug Delivery Across the Blood–Brain Barrier: Current In Vivo Evidence, Translational Challenges, and Future Perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAli A. Al‐allaqHHHussein A. HassanHHHidayet M. Hidayet

Discussion

Loading...

Member takes

Overview

Review evaluates nanoparticle drug delivery across the blood-brain barrier, highlighting challenges and future developments.

Key Points

  • This review aims to evaluate advancements in nanoparticle-based drug delivery systems targeting the blood-brain barrier and their efficacy in treating central nervous system disorders.
  • Critical evaluation of recent in vivo studies on various types of nanoparticles including lipid-based, polymeric, and metallic, among others.
  • Comparison of therapeutic efficacy, biodistribution, targeting ability, and safety of nanoparticles in different neurological conditions.
  • Discussion of emerging technologies such as biomimetic nanoparticles and artificial intelligence for personalized nanomedicine.
  • Nanoparticle-based systems show improved targeting and therapeutic efficacy compared to conventional treatments for central nervous system disorders.
  • Emerging technologies have the potential to address key challenges in drug delivery through the blood-brain barrier, although significant regulatory and biosafety issues remain.
  • Current advancements suggest promise for nanoparticles in clinical applications, but challenges in translational processes are highlighted.

Cite This Study

Al‐allaq et al. (2026) studied this question.

synapsesocial.com/papers/6a7c20ae06a85aed514b7a9ehttps://doi.org/10.3390/micro6030065
View Full Paper
Ask AI
Bookmark
Share